Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Women, the menopause, hormone replacement therapy and coronary heart disease

Whayne, Thomas F. Jra; Mukherjee, Debabratab

Current Opinion in Cardiology: July 2015 - Volume 30 - Issue 4 - p 432–438
doi: 10.1097/HCO.0000000000000157
LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Anthony S. Wierzbicki

Purpose of review Cardiovascular disease considerations are associated with the menopause. Despite a misconception that women have a minimal risk for coronary heart disease (CHD), it is the major cause of female deaths. This review highlights issues of hormone replacement therapy (HRT) and CHD in women.

Recent findings A woman under age 60, who suffers a myocardial infarction (MI), has a 2-year post-MI mortality of 28.9%; it is 19.6% in men. CHD and MI in women are subtle. In addition, female mortality from CHD increases after the menopause. The increased inflammatory risk factor status of women plays a role in development of atherosclerosis, before and after the menopause. Until after the menopause, women overall have a lower CHD mortality rate. Menopause is associated with unique symptoms, especially vasomotor ones; preexisting cardiovascular disease further exacerbates problems associated with the menopause. Use of HRT after the menopause is a major issue. Early menopause at age 39 years or younger and late menopause at age 56 years or older increase cardiovascular risk. HRT should not be prescribed for cardiovascular risk prevention, but when less than 10 years from menopause at a normal age, women can be reassured that cardiovascular risk from HRT is very low.

Summary Prescription of HRT should never be made only for cardiovascular risk reduction. However, when symptom-related and other indications are present, HRT is appropriate and well tolerated in the early years after menopause with onset at a normal age.

aDivision of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, Kentucky

bDivision of Cardiovascular Medicine, Texas Tech University HSC, and Paul Foster School of Medicine, El Paso, Texas, USA

Correspondence to Thomas F. Whayne, Jr, MD, PhD, 326 Wethington Building, 900 South Limestone Street, Lexington, KY 40536-0200, USA. Tel: +1 859 218 5332; fax: +1 859 323 6475; e-mail:

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.